AU781226B2 - Isoforms of SNARE molecules and the uses thereof in modulation of cellular exocytosis - Google Patents

Isoforms of SNARE molecules and the uses thereof in modulation of cellular exocytosis Download PDF

Info

Publication number
AU781226B2
AU781226B2 AU68526/00A AU6852600A AU781226B2 AU 781226 B2 AU781226 B2 AU 781226B2 AU 68526/00 A AU68526/00 A AU 68526/00A AU 6852600 A AU6852600 A AU 6852600A AU 781226 B2 AU781226 B2 AU 781226B2
Authority
AU
Australia
Prior art keywords
snare
toxin
snap
bont
resistant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU68526/00A
Other languages
English (en)
Other versions
AU6852600A (en
Inventor
James Oliver Dolly
Patrick G. Foran
Nadiem Mohammed
Gregory A. O'Sullivan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College Innovations Ltd filed Critical Imperial College Innovations Ltd
Publication of AU6852600A publication Critical patent/AU6852600A/en
Application granted granted Critical
Publication of AU781226B2 publication Critical patent/AU781226B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU68526/00A 1999-08-20 2000-08-18 Isoforms of SNARE molecules and the uses thereof in modulation of cellular exocytosis Ceased AU781226B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14999399P 1999-08-20 1999-08-20
US60/149993 1999-08-20
PCT/GB2000/003196 WO2001018038A2 (fr) 1999-08-20 2000-08-18 Isoformes de molecules de snare et leurs utilisations pour moduler l'exocytose cellulaire

Publications (2)

Publication Number Publication Date
AU6852600A AU6852600A (en) 2001-04-10
AU781226B2 true AU781226B2 (en) 2005-05-12

Family

ID=22532674

Family Applications (1)

Application Number Title Priority Date Filing Date
AU68526/00A Ceased AU781226B2 (en) 1999-08-20 2000-08-18 Isoforms of SNARE molecules and the uses thereof in modulation of cellular exocytosis

Country Status (5)

Country Link
EP (1) EP1210444A2 (fr)
JP (1) JP2003508092A (fr)
AU (1) AU781226B2 (fr)
CA (1) CA2379532A1 (fr)
WO (1) WO2001018038A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
GB0111146D0 (en) * 2001-05-04 2001-06-27 Imp College Innovations Ltd Methods
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7374896B2 (en) 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US8022172B2 (en) 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US20060153876A1 (en) 2003-02-24 2006-07-13 Ira Sanders Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease
US7399607B2 (en) 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
CA2588758C (fr) 2004-11-22 2017-01-03 New York University Genes clostridiaux genetiquement modifies, proteines codees par ces genes modifies et utilisations de ceux-ci
US20080260725A1 (en) * 2007-03-29 2008-10-23 Ulhas Naik Tag and target delivery system
EP2649985A1 (fr) * 2012-04-13 2013-10-16 Lipotec, S.A. Composés inhibant l'exocytosis neuronale (III)
MX356343B (es) * 2012-04-13 2018-05-23 Lubrizol Advanced Mat Inc Compuestos que inhiben la exocitosis neuronal (ii).
US9315549B2 (en) 2013-01-28 2016-04-19 New York University Treatment methods using atoxic neurotoxin derivatives
EP3230457B1 (fr) 2014-12-09 2021-06-30 New York University Protéines de fusion de neurotoxine clostridienne, fusions de propeptides, leur expression et leur utilisation
KR102274841B1 (ko) * 2019-10-16 2021-07-12 주식회사 하울바이오 Snare 복합체를 억제하는 항-snap 25 항체 및 이의 용도

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2138740T3 (es) * 1994-05-31 2000-01-16 Allergan Inc Modificacion de toxinas de clostridium utilizadas como proteinas de transporte.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIOCHEM J. 1999 VOL 339 PP 159-165 *

Also Published As

Publication number Publication date
EP1210444A2 (fr) 2002-06-05
AU6852600A (en) 2001-04-10
JP2003508092A (ja) 2003-03-04
WO2001018038A2 (fr) 2001-03-15
WO2001018038A3 (fr) 2001-10-11
CA2379532A1 (fr) 2001-03-15

Similar Documents

Publication Publication Date Title
AU781226B2 (en) Isoforms of SNARE molecules and the uses thereof in modulation of cellular exocytosis
Hayashi et al. Synaptic vesicle membrane fusion complex: action of clostridial neurotoxins on assembly.
Brin Botulinum toxin: chemistry, pharmacology, toxicity, and immunology
Poulain et al. How do the botulinum neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action
US7211261B1 (en) Stable liquid formulations of botulinum toxin
Masuyer et al. Engineered botulinum neurotoxins as new therapeutics
JP5833039B2 (ja) 神経細胞に化合物を導入するために用いられる輸送タンパク質
ES2904884T3 (es) Enzima del clostridium histolyticum
US6169074B1 (en) Peptide inhibitors of neurotransmitter secretion by neuronal cells
ES2693705T3 (es) Neurotoxinas que muestran actividad biológica reducida
US20080107673A1 (en) Mutants of clostridium difficile toxin B and methods of use
KR20100113478A (ko) 증가된 안정성을 갖는 재조합 인자 ⅴⅰⅰⅰ
JP2009513118A (ja) ボツリヌス神経毒ａタンパク質受容体およびその使用
CA2483658A1 (fr) Bont/e ou snap-25e utilises pour traiter une intoxication a la toxine botulique a ou c1 et inhiber la contraction musculaire
CA1341048C (fr) Methode et compositions pour la production de facteurs stimulateurs de l'adenylate cyclase (fsac) et de leurs antagonistes
US5668106A (en) Method and compositions for making ACSF and ACSF antagonists
Bakry et al. Expression of botulinum toxin binding sites in Xenopus oocytes
Simpson et al. The role of exoproteases in governing intraneuronal metabolism of botulinum toxin
AU2011244911B2 (en) Non-cytotoxic protein conjugates
EP1506231A2 (fr) Polypeptides hybrides et polypeptides de fusion de sous-unites de caneaux k+
Neale et al. Clostridial neurotoxins and membrane traffic at the synaptic terminal
DUPONT et al. Emmanuel lovER", Fréderig DoussAU", Etienne LoNCHAMP", Laetitia woLAND", Jean
Dolly et al. Development of Targeted Therapeutic Agents for Botulism